Medicare AdvantagePrior AuthMedium impact
Kalbitor (ecallantide) (Revised)
Humana·KY, SC · Allergy & Immunology, Internal Medicine, Emergency Medicine·Medicaid
Effective date
Jan 1, 2025
We identified it
Jul 21, 2026
Summary
Humana has revised its prior authorization policy for Kalbitor (ecallantide) for treatment of acute hereditary angioedema (HAE) attacks effective January 1, 2025. The policy now applies to Medicare and Medicaid (Kentucky and South Carolina) and requires comprehensive documentation including HAE type confirmation, specific lab values (C4, C1INH levels, C1q), specialist treatment, and step therapy documentation (trial/contraindication/intolerance to generic icatibant) for coverage. Note: Medicaid members are exempt from step therapy requirements, while Medicare Part B members may be exempt if continuing prior therapy within 365 days.
Action Required
By January 1, 2025: Billing and clinical teams must implement prior authorization workflow for Kalbitor requests. (1) Update billing system to require prior authorization submission for all Kalbitor claims. (2) Create prior auth checklist requiring documentation of: HAE Type 1 or 2 diagnosis, lab values (C4 level, C1INH antigenic/functional level or C1INH mutation, and C1q level), evidence of recurrent angioedema without urticaria, exclusion of concomitant angioedema-causing medications (ACEIs, ARBs), specialist treatment (allergist/immunologist), and step therapy documentation for Medicare Part B claims only (trial of generic icatibant with response, contraindication, or side effect documentation). (3) For Medicaid (KY, SC) claims, do NOT require step therapy documentation. (4) For Medicare Part B continuation therapy claims within 365 days, waive step therapy requirement. (5) Train providers and front desk staff that Kalbitor requires prior authorization before dispensing. (6) Update encounter forms to capture required documentation fields. Failure to obtain proper prior authorization or submit complete documentation will result in claim denials.